Mergers and Acquisitions

Mergers and Acquisitions Articles

Perhaps not since Apple paid $3 billion for Beats has a company overpaid so much for a music company. An injection of dollars from Sprint is unlikely to solve Tidal's basic problems.
Credit Suisse sees future earnings growth from Incyte’s pipeline, with epacadostat’s potential as a best-in-class immunotherapy combination agent making the stock an attractive takeout target.
If the Trump administration wants to show its disdain for larger mergers that it believes are not in the public's best interests by killing the deal, Time Warner shares probably will reset.
Aerospace industry merger between Safran and Zodiac to create world's third-largest supplier to the industry. Deal is worth about $9.7 billion, including assumption of Zodiac's debt.
The stocks of Tronc and Gannett were thrown out of what would have been a normal trajectory by merger talks. Now they can move according to results.
This acquisition not only will enhance Eli Lilly's existing portfolio in pain management for migraine, but it also adds a potential near-term launch to its late-stage pipeline.
The $49 billion acquisition of Reynolds American tobacco by British American Tobacco is a play for survival in a world where tobacco use is falling as prices and restrictions increase.
Noble Energy to acquire Clayton Williams Energy in a cash-and-stock deal worth more than $3 billion, including debt. Noble more than doubles its acreage in the Permian Basin of west Texas.
If there is one area of the United States that continues to enchant and enthrall energy investors and operators alike, it would have to be the Permian Basis.
Meredith may be in the midst of a merger with America's largest magazine publisher, but Wall Street, ironically, loves the company because magazines are not its most successful business.
ClubCorp has confirmed the potential sale rumors, announcing that its board of directors has established a strategic review committee to evaluating alternatives in an effort to further enhance...
Biotech and pharma companies were on the move Wednesday. A few of the smaller caps made tremendous gains on the day, while a couple of the major firms saw massive volume and a slight move. Although...
Valeant Pharmaceuticals made waves early on Tuesday after the company offered announcements of a late-stage psoriasis trial and the sale of a couple business segments.
Mergers and acquisitions are a way for companies to come together and complement each other’s business models. However, one acquisition stood out on Monday that had some investors scratching their...
As the second week of the New Year is now underway, a few biotech companies made sizable runs to kick off the week.